Kombinierte Verwendung eines Antikörper-Wirkstoff-Konjugats und eines Immuncheckpoint-Inhibitors
EP4796123
24. April 2025
Anmelder: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Company Limited, Changzhou Hansoh Pharmaceutical Company Limited 🇨🇳
Details
- Veröffentlichungs-Nr.
- EP4796123
- Anmeldetag
- 17. Oktober 2024
- Veröffentlichung
- 24. April 2025
- Rechtsraum
- EP
- IPC
- A61K39/395, A61P35/00
Abstract
Provided is a use of an antibody-drug conjugate alone or in combination in the preparation of drugs for preventing and/or treating cancer. Specifically, provided is a use of an antibody-drug conjugate or a pharmaceutically acceptable salt, metabolite or solvent compound thereof alone or in combination with an immune checkpoint inhibitor in the preparation of drugs for preventing and/or treating cancer.
Anmelder
- Firmen
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Shanghai Hansoh Biomedical Company Limited
Changzhou Hansoh Pharmaceutical Company Limited - Land
- 🇨🇳 China
Fachgebiete
Vertreten von
Hanby, Abigail Rose
London, Großbritannien
5
Patente gesamt
2
Fachgebiete
1
Anmelder-Länder
Schwerpunkte